Cognition Therapeutics Inc (NAS:CGTX)
$ 2.55 -0.05 (-1.92%) Market Cap: 102.15 Mil Enterprise Value: 70.52 Mil PE Ratio: 0 PB Ratio: 3.60 GF Score: 22/100

Cognition Therapeutics Inc to Discuss Topline Results From Phase 2 Sequel Clinical Update Call Transcript

Jun 28, 2023 / 12:00PM GMT
Release Date Price: $2.18 (-12.80%)
Operator

Good morning, ladies and gentlemen, and welcome to Cognition Therapeutics Sequel Study Clinical Update Conference Call and Webcast. My name is Sarah, and I will be your conference operator today. This call is being recorded. I would like to turn the presentation over now to your host for today's call -- sorry, Mr. Daniel Kontoh-Boateng, Investor Relations for Cognition Therapeutics. Please proceed, Mr. Kontoh-Boateng.

Daniel Kontoh;Boateng

Good morning, and thank you for participating in Cognition Therapeutics conference call and webcast today. With me today are Lisa Ricciardi, President and Chief Executive Officer of Cognition; Anthony Caggiano, Chief Medical Officer and Head of R&D of Cognition and Willem de Haan, neurologist and senior researcher of Amsterdam University Medical Center.

A press release of the company's Phase II SEQUEL study results is available in the Investors section of the company's investor website. In addition, this conference call is being webcast through the company's website and will be archived for 90 days.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot